Adenovirus DNA Polymerase Loses Fidelity on a Stretch of Eleven Homocytidines during Pre-GMP Vaccine Preparation

In this study, we invented and construct novel candidate HIV-1 vaccines. Through genetic and protein engineering, we unknowingly constructed an HIV-1-derived transgene with a homopolymeric run of 11 cytidines, which was inserted into an adenovirus vaccine vector. Here, we describe the virus rescue, three rounds of clonal purification and preparation of good manufacturing practise (GMP) starting material assessed for genetic stability in five additional virus passages. Throughout these steps, quality control assays indicated the presence of the transgene in the virus genome, expression of the correct transgene product and immunogenicity in mice. However, DNA sequencing of the transgene revealed additional cytidines inserted into the original 11-cytidine region, and the GMP manufacture had to be aborted. Subsequent analyses indicated that as little as 1/25th of the virus dose used for confirmation of protein expression (106 cells at a multiplicity of infection of 10) and murine immunogenicity (108 infectious units per animal) met the quality acceptance criteria. Similar frameshifts in the expressed proteins were reproduced in a one-reaction in vitro transcription/translation employing phage T7 polymerase and E. coli ribosomes. Thus, the most likely mechanism for addition of extra cytidines into the ChAdOx1.tHIVconsv6 genome is that the adenovirus DNA polymerase lost its fidelity on a stretch of 11 cytidines, which informs future adenovirus vaccine designs.

[1]  B. Korber,et al.  Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines , 2021, Molecular therapy. Methods & clinical development.

[2]  John C W Lim,et al.  Measuring Progress of Regulatory Convergence and Cooperation Among Asia–Pacific Economic Cooperation (APEC) Member Economies in the Context of the COVID-19 Pandemic , 2021, Therapeutic Innovation & Regulatory Science.

[3]  Wei Zhou,et al.  Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak , 2020, Biotechnology progress.

[4]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[5]  A. Franklin,et al.  A proposed reverse transcription mechanism for (CAG)n and similar expandable repeats that cause neurological and other diseases , 2020, Heliyon.

[6]  B. Korber,et al.  T cell-based strategies for HIV-1 vaccines , 2019, Human vaccines & immunotherapeutics.

[7]  T. Hanke Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials , 2019, Expert review of vaccines.

[8]  B. Clotet,et al.  Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study) , 2019, EClinicalMedicine.

[9]  S. Faust,et al.  Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults , 2018, EBioMedicine.

[10]  W. Jaoko,et al.  Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults , 2016, Molecular therapy. Methods & clinical development.

[11]  A. McMichael,et al.  Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  E. Karita,et al.  A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults , 2015, PloS one.

[13]  T. Hanke,et al.  Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial , 2014, PloS one.

[14]  Lucy Dorrell,et al.  Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  W. Wold,et al.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. , 2014, Current gene therapy.

[16]  A. Hill,et al.  Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  Jennifer A. Johnson,et al.  Nonreplicating vectors in HIV vaccines. , 2013, Current opinion in HIV and AIDS.

[18]  Taco G. Uil,et al.  Adenovirus DNA replication. , 2013, Cold Spring Harbor perspectives in biology.

[19]  K. Bojang,et al.  A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity , 2012, PloS one.

[20]  B. Haynes,et al.  Lessons learned from HIV-1 vaccine trials: new priorities and directions , 2012, Nature Immunology.

[21]  Ad Davidson,et al.  Chromatin structure of adenovirus DNA throughout infection , 2011, Nucleic acids research.

[22]  Fernando Castro-Chavez,et al.  Most Used Codons per Amino Acid and per Genome in the Code of Man Compared to Other Organisms According to the Rotating Circular Genetic Code. , 2011, NeuroQuantology : an interdisciplinary journal of neuroscience and quantum physics.

[23]  C. Turnbough,et al.  Regulation of gene expression by reiterative transcription. , 2011, Current opinion in microbiology.

[24]  D. Raab,et al.  The GeneOptimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization , 2010, Systems and Synthetic Biology.

[25]  D. Barouch Novel adenovirus vector-based vaccines for HIV-1 , 2010, Current opinion in HIV and AIDS.

[26]  S. Plotkin,et al.  Vaccines: the Fourth Century , 2009, Clinical and Vaccine Immunology.

[27]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[28]  F. He,et al.  Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. , 2006, Vaccine.

[29]  S. Mittal,et al.  Development of nonhuman adenoviruses as vaccine vectors , 2005, Vaccine.

[30]  D. Webster,et al.  Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers1 , 2005, The Journal of Immunology.

[31]  M. Ison,et al.  Adenovirus , 2016, Microbiology spectrum.

[32]  Hildegund C.J. Ertl,et al.  Adenoviruses as vaccine vectors , 2004, Molecular Therapy.

[33]  A. Moore,et al.  Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria , 2004, Immunological reviews.

[34]  A. Davison,et al.  Genetic content and evolution of adenoviruses. , 2003, The Journal of general virology.

[35]  L. M. Albright Vectors , 2003, Current protocols in molecular biology.

[36]  S. Yokoyama,et al.  Structure of a T7 RNA polymerase elongation complex at 2.9 Å resolution , 2002, Nature.

[37]  A. Hill,et al.  Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. , 2002, Vaccine.

[38]  Takuya Ueda,et al.  Cell-free translation reconstituted with purified components , 2001, Nature Biotechnology.

[39]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[40]  P. Travers,et al.  The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. , 1998, Journal of immunology.

[41]  J. Haas,et al.  Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage , 1998, Journal of Virology.

[42]  F. Graham,et al.  Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides , 1991, Journal of virology.

[43]  S. Zolla-Pazner,et al.  Generation of human monoclonal antibodies to human immunodeficiency virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. C. van der Vliet,et al.  Temperature-sensitive initiation and elongation of adenovirus DNA replication in vitro with nuclear extracts from H5ts36-, H5ts149-, and H5ts125-infected HeLa cells , 1983, Journal of virology.

[45]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[46]  James Theiler,et al.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.

[47]  C. Peter,et al.  3 Roles of Transcription Factors in DNA Replication , 1996 .

[48]  J. Majors Translational frameshift suppression in mouse mammary tumor virus and other retroviruses. , 1990, Enzyme.

[49]  W. French Anderson,et al.  Transcription of single base oligonucleotides by ribonucleic acid- directed deoxyribonucleic acid polymerase , 1976, Nucleic Acids Res..

[50]  M. Chamberlin,et al.  DEOXYRIBONUCLEIC ACID-DIRECTED SYNTHESIS OF RIBONUCLEIC ACID BY AN ENZYME FROM ESCHERICHIA COLI , 1962 .

[51]  W. Bailey History of Vaccination. , 1899, Public health papers and reports.